Vous êtes ici

Variabilité des symptômes de la BPCO : la variabilité du « stimulus »

T. Similowski,*, M. Decavèle

Références


[1] McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic infl ammation, and cardiovascular disease. Am J Respir Crit Care Med 2009;180:692-700.

[2] GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. 2013 [update 2013]; Available from www.goldcopd.org/ uploads/users/fi les/GOLD_Report_2013_Feb20

[3] Van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case fi nding study. BMJ 2002;324:1370-4.

[4] Bellamy D, Bouchard J, Henrichsen S, Johansson G, Langhammer A, Reid J, et al. International primary care respiratory grow-up (ICPRG) guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006;15:48-57.

[5] Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.

[6] Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airfl ow limitation in chronic obstructive pulmonary disease. Thorax 2003;58:855-60.

[7] Van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airfl ow obstruction and resting hyperinfl ation in patients with COPD. Chest 2006;129:509-17.

[8] Postma DS, Koëter GH, vd Mark TW, Reig RP, Sluiter HJ. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airfl ow obstruction. Chest 1985;87:653-7.

[9] Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PM. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 1990;45:190-4.

[10] Casale R, Pasqualetti P. Cosinor analysis of circadian peak expiratory fl ow variability in normal subjects, passive smokers, heavy smokers, patients with chronic obstructive pulmonary disease and patients with interstitial lung disease. Respiration 1997;64:251-6.

[11] Dawkins KD, Muers MF. Diurnal variation in airfl ow obstruction in chronic bronchitis. Thorax 1981;36:618-21.

[12] Kim YJ, Lee BK, Jung CY, Jeon YJ, Hyun DS, Kim KC, Yu SK, Choi HS, Shin WH, Lee KH. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study. Korean J Intern Med 2012;27:426-35. [13] Hammond E. Some preliminary fi ndings on physical complaints from a prospective study of 1,064,004 men and women. Am J Public Health 1964;54:11-23.

[14] Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009;3:1–11. [15] ATS ad hoc Committee. Dyspnea Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999;159:321-40.

[16] Lansing RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnea: review and hypotheses. Respir Physiol Neurobiol 2009;167:53-60.

[17] Killian KJ, Watson R, Otis J, ST. Amand TA, O’Byr PM. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med 2000;162:490-6.

[18] Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantifi cation of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax 2010;65:21-6.

[19] Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European crosssectional study. Eur Respir J 2011;37:264-72.

[20] Moy ML, Weiss JW, Sparrow D, Israel E, Schwartzstein RM. Quality of dyspnea in bronchoconstriction differs from external resistive loads. Am J Respir Crit Care Med 2000;162:451-5. [21] Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Löfdahl CG, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interviewbased study. Chest 2006;130:133-42.

[22] Haughney J, Partridge MR, Vogelmeier C, Larsson T, Kessler R, Ståhl E, et al. Exacerbations of COPD: quantifying the patient’s perspective using discrete choice modelling. Eur Respir J 2005;26:623–9.

[23] Banzett RB, Mulnier HE, Murphy K, Rosen SD, Wise RJ, Adams L. Breathlessness in humans activates insular cortex. Neuroreport 2000;11:2117-20.

[24] Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez- Izquierdo J, et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J 2010;36:292–300.

[25] Marey EJ. Études graphiques des mouvements respiratoires. Comptes rendus des séances et mémoires de la société de biologie 1864;1:175-81.

[26] Que CL, Kenyon CM, Olivenstein R, Macklem PT, Maksym GN. Homeokinesis and short-term variability of human airway caliber. J Appl Physiol 2001;91:1131-41.

[27] Teulier M, Fiamma MN, Straus C, Similowski T. Acute bronchodilation increases ventilatory complexity during resting breathing in stable COPD: toward mathematical biomarkers of ventilatory function? Respir Physiol Neurobiol 2013;185:477-80.

[28] Mangin L, Fiamma MN, Straus C, Derenne JP, Zelter M, Clerici C, et al. Respir Source of human ventilatory chaos: lessons from switching controlled mechanical ventilation to inspiratory pressure support in critically ill patients. Physiol Neurobiol 2008;161:189-96

[29] Samara Z, Raux M, Fiamma MN, Gharbi A, Gottfried SB, Poon CS, et al. Effects of inspiratory loading on the chaotic dynamics of ventilatory flow in humans. Respir Physiol Neurobiol 2009;165:82-9.

[30] Fiamma MN, Straus C, Thibault S, Wysocki M, Baconnier P, Similowski T. Effects of hypercapnia and hypocapnia on ventilatory variability and the chaotic dynamics of ventilatory flow in humans. Am J Physiol Regul Integr Comp Physiol 2007;292:R1985–93.

[31] Poon CS, Barahona M. Titration of chaos with added noise. Proc Natl Acad Sci USA 2001;98:7107–12.

[32] Schmidt M, Demoule A, Cracco C, Gharbi A, Fiamma MN, Straus C, et al. Neurally adjusted ventilatory assist increases respiratory variability and complexity in acute respiratory failure. Anesthesiology 2010;112:670-81. [33] Wysocki M, Cracco C, Teixeira A, Mercat A, Diehl JL, Lefort Y, et al. Reduced breathing variability as a predictor of unsuccessful patient separation from mechanical ventilation. Crit Care Med 2006;34:2076-83.

[34] Bien MY, Shui Lin Y, Shih CH, Yang YL, Lin HW, Bai KJ, et al. Comparisons of predictive performance of breathing pattern variability measured during T-piece, automatic tube compensation, and pressure support ventilation for weaning intensive care unit patients from mechanical ventilation. Crit Care Med 2011;39:2253-62.

[35] Frey U, Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet 2008;372:1088-99.

[36] Brack T, Jubran A, Tobin MJ. Dyspnea and decreased variability of breathing in patients with restrictive lung disease. Am J Respir Crit Care Med 2002;165:1260-4.

Auteurs correspondants


*Auteur correspondant.
Adresse e- mail : thomas.similowski@psl.aphp.fr (T. Similowski).

Auteurs


T. Similowski1,*, M. Decavèle2

1Service de pneumologie et réanimation médicale, Groupe hospitalier Pitié-Salpêtrière Charles Foix ; ER 10 UPMC Neurophysiologie respiratoire expérimentale et clinique ; Université Paris 6, Pierre-et-Marie-Curie Paris, France
2DES pneumologie Ile-de-France, DESC réanimation médicale ; Service de pneumologie et réanimation, Groupe hospitalier Pitié-Salpêtrière, 47-83 boulevard de l’Hôpital, 75013 Paris, France

Liens d'intérêts


  • T. Similowski a perçu de la part d’Almirall France une rémunération pour la préparation du séminaire duquel cet article est dérivé et sa participation à ce séminaire. Il a été rémunéré par ailleurs par Almirall France pour sa participation à un comité d’experts constitué à propos du bromure d’aclidinium (Eklira®), et en tant que conseiller scientifi que indépendamment de ce groupe d’experts. Il a participé à une réunion internationale organisée par Almirall Corporate. Par ailleurs, il a perçu au cours des cinq dernières années des honoraires ou fi nancements pour participation à des congrès, communications, actions de formation et de conseil, des groupes d’experts, travaux de recherche, de la part des laboratoires/entreprises AstraZeneca France, AstraZeneca Corporate, Boehringer- Ingelheim France, GlaxoSmithKline France, Medapharma, Menarini, MSD France, Novartis Pharma France, Novartis Corporate, Pierre Fabre, Pfi zer France. M.
  • Decavèle a declaré n’avoir aucun lien d’intérêts pour cet article.